蒽环类化疗（以及胸部放疗）可导致慢性、剂量依赖性的心脏损伤，这种损伤可能在治疗多年后才出现或加重。
原始表述
سمية قلبية مزمنة من الأنثراسايكلين
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
蒽环类化疗（以及胸部放疗）可导致慢性、剂量依赖性的心脏损伤，这种损伤可能在治疗多年后才出现或加重。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (rule page summary/narrative)
- 出处
- https://eltayebat.com/rule/chemo-radiation/
- 归属的不确定性
- Written by archive operators; not attributed to Elawady.
- 所声称的机制
Myocyte loss; radiation-induced coronary and myocardial damage
- 所声称的健康影响
Heart failure, coronary disease, valvular/pericardial disease
- 涉及人群
Patients treated with anthracyclines or chest radiotherapy; childhood-cancer survivors
- Elawady 设定的地域限制
none found
科学评估
正确 – 该说法有可靠证据支持。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Anthracyclines cause chronic cardiotoxicity; late cardiac disease in survivors.
2. 哪些内容可证实是正确的？
Correct. Cardiotoxicity occurred in 9% of 2,625 anthracycline-treated patients, mostly within the first year and dose-related (A-CHM-01); childhood survivors show dose-related late cardiac abnormalities and 5-6-fold relative hazards of heart failure versus siblings (A-CHM-02, A-CHM-03).
3. 哪些内容是错误或夸大的？
Nothing material. The archive omits that most early-detected cases recovered fully or partly under heart-failure therapy (11% full, 71% partial; A-CHM-01).
4. 哪些内容仍不明确？
Absolute long-term risks under current lower-dose protocols: in randomised adjuvant breast cancer trials, adding anthracycline did not increase cardiovascular death within a median 5.4 years (I-CHM-101), whereas at high cumulative doses heart failure was frequent (estimated 26% at 550 mg/m2 doxorubicin; I-CHM-108).
5. 哪些研究支持该说法？
A-CHM-01, A-CHM-02, A-CHM-03, A-CHM-05 (severe cardiac events 2.9-4.1% with trastuzumab), I-CHM-06 (cardiac mortality RR 1.30 after radiotherapy).
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
Cardio-oncology surveillance and prevention are part of European practice: the 2022 ESC cardio-oncology guideline (first ESC guideline on the topic) covers definition, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after treatment (ESC guideline page fetched 2026-10-26; detailed recommendations not audited). Dexrazoxane reduced clinical heart failure in adults by about four-fifths without reducing cancer control (RR 0.22, 0.11-0.43; I-CHM-109).
8. 关于埃及的已知情况是什么？
Anthracyclines and chest radiotherapy are used in Egypt. The Egyptian Society of Cardiology is listed among the national societies endorsing the 2022 ESC cardio-oncology guideline. No Egyptian data on the frequency of cardiotoxicity in patients were found (searches found mainly animal studies).
9. 合理的实际结论是什么？
远期心脏影响是进行监测和预防的理由，而不是拒绝根治性治疗的理由。
评估详情
- 证据确定性的依据
- 来源质量
Archive editorial summarising peer-reviewed cohorts; numbers checked against abstracts.
- 地区可推广性
High.
- 个体例外情况
Risk higher with higher cumulative dose, young age, pre-existing cardiac risk factors.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
有充分科学证据支持 – 该说法与一致的高质量证据相符。
研究问题: In patients treated with anthracyclines or chest radiotherapy, does treatment cause chronic, dose-dependent cardiac damage that can appear or progress years later, and how large is the absolute risk?
研究问题详解 (PECO)
- 人群
- Adults and children treated with anthracyclines and/or chest radiotherapy
- 干预或暴露
- Anthracycline chemotherapy (cumulative dose); radiation dose to the heart
- 对照
- Lower or no exposure; siblings/general population
- 地域范围
- universal biology
- 结局指标
- Heart failure
- LVEF decline
- Coronary, valvular, pericardial disease
- Cardiovascular death
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Adult survivors of childhood cancer have more heart disease than their siblings
Adult survivors of childhood cancer had much more heart disease than siblings, rising with anthracycline dose and cardiac radiation dose.
- 实际结果
- CHF HR 5.9 (3.4-9.6) vs siblings; anthracycline >=250 mg/m2 CHF HR 5.2 (3.6-7.4); prevalence CHF 1.7% vs 0.2%
- 方法学质量
- moderate-high (large cohort, full text read)
- 相关性
- direct
- 局限
- Self-reported outcomes; older treatment eras
Heart failure after doxorubicin by dose
Pooled doxorubicin arms of three phase III trials: heart failure risk rose steeply with cumulative dose.
- 实际结果
- 32/630 (5.1%) CHF; estimated 26% at 550 mg/m2
- 方法学质量
- moderate (trial data, retrospective analysis)
- 相关性
- direct
- 局限
- High cumulative doses not typical of current adjuvant regimens
Heart damage after anthracycline chemotherapy is common in the first year
Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777 队列研究已核查摘要Prospective cohort with systematic echocardiography: 9% cardiotoxicity, dose-related, mostly in the first year.
- 实际结果
- 226/2625; HR 1.09 per 50 mg/m2; 82% full or partial recovery with treatment
- 方法学质量
- moderate (single-centre prospective)
- 相关性
- direct
- 局限
- Single centre; LVEF definition
哪些证据不支持该说法？
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4 Meta分析已核查全文新增In randomised trials of modern adjuvant regimens, adding anthracycline did not increase cardiovascular death or death without recurrence over a median 5.4 years.
- 实际结果
- No significant difference in death without recurrence, including cardiovascular death
- 方法学质量
- high (IPD meta-analysis)
- 相关性
- direct for short-term mortality; does not address late effects
- 局限
- Short follow-up; high cardiac-risk patients often excluded
Can heart damage from anthracyclines be prevented?
de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2 Meta分析已核查摘要新增Dexrazoxane reduced heart failure in adults without reducing cancer control, showing the harm is modifiable.
- 实际结果
- RR 0.22 (0.11-0.43)
- 方法学质量
- high (Cochrane, moderate-certainty outcome)
- 相关性
- indirect (limits severity, not existence)
- 局限
- Paediatric second-cancer signal
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Anthracycline and chest-radiation cardiotoxicity is real, dose-dependent and can appear years later.
为什么有些研究权重更大
Large cohorts with dose-response and trial-based dose analyses weigh most; the EBCTCG result limits only the size of short-term fatal cardiac risk at modern doses, not the existence of chronic damage.
因果关系是否已确立？ 是，已确立 Consistent dose-response across cohorts and trial arms, biological mechanism, reversibility with prevention (dexrazoxane).
仍存在的不确定性
Absolute lifetime risk under current lower-dose regimens and modern radiotherapy.
合理的结论
The claim is correct. Absolute risks depend strongly on dose: several percent at high cumulative doses, low at modern adjuvant doses, and the harm is monitored and partly preventable.
为什么研究结果看起来互相矛盾？
Cohorts (A-CHM-01..03, I-CHM-108) find frequent cardiotoxicity while EBCTCG 2023 found no excess cardiovascular death. They answer different questions: subclinical/clinical heart dysfunction over many years at higher doses versus fatal cardiac events within about 5 years at modern doses in selected trial patients.
这是否取决于国家？
- 一般生物学效应
- Universal pharmacology and radiobiology.
- 饮食习惯
- Not relevant.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- Egyptian cardiotoxicity research found was mainly animal/mechanistic; no Egyptian incidence data reviewed.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Crude proportion vs model-based cumulative incidence – 32/630 = 5.1% crude; 26% at 550 mg/m2 is a model estimate and cannot be recomputed 已重新计算
- Absolute excess from reported prevalences – CHF +1.5, MI +0.5, pericardial +1.0, valvular +1.1 percentage points vs siblings 已重新计算
- Log-symmetry of RR 0.22 (0.11-0.43) – Symmetric (0.693 vs 0.670); plausible 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Chronic heart dysfunction/heart failure after anthracyclines
- 起始等级
- 低（观察性研究）
- 升级理由
- dose-response
- large effect (HR about 5 at high doses)
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ESC: 2022 ESC Guidelines on cardio-oncology (with EHA, ESTRO, IC-OS) (2022) · 原始文献
The ESC guideline page states that this first ESC cardio-oncology guideline covers definitions, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after cancer treatment, and that evidence is limited so expert consensus is used where needed. The page lists the Egyptian Society of Cardiology among endorsing national societies. Detailed recommendations (full text, Eur Heart J 2022; PMID 36017568) could not be fetched (HTTP 403) and were not used.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:"congestive heart failure" AND TITLE:"doxorubicin" AND (TITLE:"retrospective analysis of three trials" OR AUTH:"Swain SM") | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (TITLE:"cardiotoxicity" OR TITLE:"heart failure") AND TITLE:"anthracycline" AND (TITLE:"meta-analysis" OR TITLE:"systematic review") AND (TITLE:"incidence" OR TITLE:"risk") AND PUB_YEAR:[2015 TO 2026] | 支持性证据 | 1 | |
| PubMed | 2026年10月26日 | (cardiotoxicity[ti] OR "heart failure"[ti]) AND (anthracycline*[ti]) AND (incidence[ti] OR risk[ti]) AND (meta-analysis[pt] OR systematic review[pt]) | 支持性证据 | 7 | |
| Europe PMC | 2026年10月26日 | TITLE:"Cardioprotective interventions for cancer patients receiving anthracyclines" | 反对性证据 | 3 | |
| Europe PMC | 2026年10月26日 | TITLE:"dexrazoxane" AND JOURNAL:"Cochrane Database Syst Rev" AND PUB_YEAR:[2012 TO 2026] | 反对性证据 | 1 | |
| PubMed | 2026年10月26日 | "Early Breast Cancer Trialists Collaborative Group"[Corporate Author] AND Lancet[ta] AND 2012:2026[dp] | 双向 | 12 | |
| Europe PMC | 2026年10月26日 | (TITLE:"cardiotoxicity" OR TITLE:"cardiac dysfunction") AND (TITLE:"anthracycline" OR TITLE:"doxorubicin") AND (Egypt OR Egyptian) AND PUB_YEAR:[2015 TO 2026] | 双向 | 137 | |
| PubMed | 2026年10月26日 | "cardio-oncology"[ti] AND Lyon AR[au] AND Eur Heart J[ta] AND 2022[dp] | 指南 | 3 |
待解决的问题
Lifetime absolute risk with current regimens and cardiac-sparing radiotherapy.
核查深度如何？
9 项相关研究：2 项核查了全文（其中 1 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
一些化疗药物（蒽环类药物）以及靠近心脏部位的放疗可能会削弱心脏功能。剂量越大，风险越高。大多数问题出现在第一年内，如果及早发现，通常可以治疗。儿童期癌症幸存者在日后生活中患心脏病的比例高于他们的兄弟姐妹。因此，医生会在治疗期间和治疗后检查心脏功能。
与该说法相关的研究
支持该说法的研究 (6)
-
Heart damage after anthracycline chemotherapy is common in the first year
Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777队列研究被 Tayebat 档案网站引用已核查摘要About 9 in 100 patients developed a measurable drop in heart pumping function, mostly within one year; most recovered fully or partly with heart medication.
Incidence and dose-dependence of cardiotoxicity
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure how often and when anthracyclines damage the heart.
- 研究是如何开展的？
Prospective cohort with repeated echocardiography.
- 研究了多少人、动物或样本？
2,625 patients.
- 实际发现了什么？
9% cardiotoxicity, 98% within the first year, dose-related.
- 观察到的效应有多大？
HR 1.09 per 50 mg/m2 doxorubicin.
- 研究结果对日常生活意味着什么？
Heart monitoring during and after anthracycline therapy is important.
- 该研究有哪些局限？
Single centre, no untreated group.
- 它对 Elawady 的具体说法说明了什么？
Confirms the harm exists; does not weigh it against cancer-survival benefit.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That anthracyclines do more harm than good.
-
Doxorubicin in childhood can affect heart growth years later
Lipshultz SE et al.. N Engl J Med 1991 · PMID 1997853 · DOI 10.1056/NEJM199103213241205队列研究被 Tayebat 档案网站引用已核查摘要More than half of 115 childhood leukaemia survivors had heart function abnormalities, more often at higher doses.
Late, dose-related cardiac effects in children
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess late heart effects of doxorubicin.
- 研究是如何开展的？
Cardiac testing of survivors.
- 研究了多少人、动物或样本？
115 survivors.
- 实际发现了什么？
Dose-dependent abnormalities, progressive afterload rise.
- 观察到的效应有多大？
65% abnormal at >=228 mg/m2.
- 研究结果对日常生活意味着什么？
Childhood cancer survivors need long-term heart follow-up.
- 该研究有哪些局限？
Small, old doses, no control group.
- 它对 Elawady 的具体说法说明了什么？
Supports existence of late harm.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Whether leaving leukaemia untreated would be better (it is not).
-
Adult survivors of childhood cancer have more heart disease than their siblings
Mulrooney DA et al.. BMJ 2009 · PMID 19996459 · DOI 10.1136/bmj.b4606队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Survivors reported heart failure about 6 times as often as siblings (1.7% vs 0.2%); by 30 years after diagnosis about 4% had heart failure. Risk rose with anthracycline dose and heart radiation.
Late cardiac disease
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Quantify late heart disease in survivors.
- 研究是如何开展的？
Retrospective cohort with questionnaires.
- 研究了多少人、动物或样本？
14,358 survivors, 3,899 siblings.
- 实际发现了什么？
HR 5.9 CHF, 5.0 MI, 6.3 pericardial, 4.8 valvular versus siblings; 30-year cumulative incidence of CHF 4.1%.
- 观察到的效应有多大？
Relative hazards 5-6; absolute: CHF in 1.7% of survivors vs 0.2% of siblings.
- 研究结果对日常生活意味着什么？
Lifelong heart follow-up for survivors.
- 该研究有哪些局限？
Self-reported, unvalidated diagnoses; possible surveillance bias; few cardiovascular risk factors measured; treatments from 1970-1986.
- 它对 Elawady 的具体说法说明了什么？
Supports existence of late harm.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
Absolute risk per patient; that treatment should have been avoided.
-
Radiation dose to the heart during breast-cancer radiotherapy raises later heart-attack risk
Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825病例对照研究被 Tayebat 档案网站引用已核查摘要★ 关键研究Each extra Gray of average heart dose increased the rate of major coronary events by about 7%.
Radiation cardiotoxicity
该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure heart risk by radiation dose.
- 研究是如何开展的？
Case-control with dose reconstruction.
- 研究了多少人、动物或样本？
2,168 women.
- 实际发现了什么？
+7.4% per Gy, linear.
- 观察到的效应有多大？
ERR 7.4%/Gy (2.9-14.5).
- 研究结果对日常生活意味着什么？
Keep heart dose as low as possible; control cardiac risk factors.
- 该研究有哪些局限？
Historical doses; relative measure.
- 它对 Elawady 的具体说法说明了什么？
Confirms the archive number.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That radiotherapy does net harm.
-
With modern techniques, radiotherapy's heart and lung risks are small for non-smokers
Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722Meta分析独立交叉核查已核查摘要★ 关键研究About 0.3% risk of radiation-related heart death or lung cancer in non-smokers, higher in smokers.
Cardiac mortality RR 1.30
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate absolute RT risks.
- 研究是如何开展的？
Dose review + IPD meta-analysis.
- 研究了多少人、动物或样本？
40,781 women.
- 实际发现了什么？
Small absolute risks; smoking key.
- 观察到的效应有多大？
Cardiac mortality RR 1.30.
- 研究结果对日常生活意味着什么？
Stop smoking before/after radiotherapy.
- 该研究有哪些局限？
Smoking modelled.
- 它对 Elawady 的具体说法说明了什么？
Puts Darby in perspective.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
Individual dose-specific risk.
-
Heart failure after doxorubicin by dose
Swain SM et al.. Cancer 2003 · PMID 12767102 · DOI 10.1002/cncr.11407队列研究独立交叉核查已核查摘要★ 关键研究About 5% of 630 patients developed heart failure; risk rose steeply at high cumulative doses (26% estimated at 550 mg/m2).
Dose-dependent heart failure with doxorubicin.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Estimate heart failure risk by dose
- 研究是如何开展的？
Re-analysis of three trials
- 研究了多少人、动物或样本？
630 patients
- 实际发现了什么？
Risk climbs with dose and age
- 观察到的效应有多大？
26% at 550 mg/m2 (model estimate)
- 研究结果对日常生活意味着什么？
This is why doctors cap the total dose and monitor the heart
- 该研究有哪些局限？
High doses, old trials
- 它对 Elawady 的具体说法说明了什么？
Supports the dose-dependence claim
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot give risk for modern low-dose regimens
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (0)
该组中没有研究。
结果不一或不明确的研究 (3)
-
Adding trastuzumab to chemotherapy halved recurrence in HER2-positive breast cancer
Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Fewer recurrences and a third fewer deaths; serious heart problems in about 3-4 in 100 treated women.
Cardiac events 2.9-4.1%
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test trastuzumab added to chemotherapy.
- 研究是如何开展的？
Two RCTs analysed jointly.
- 研究了多少人、动物或样本？
Operable HER2+ breast cancer.
- 实际发现了什么？
HR 0.48 for events; 33% fewer deaths.
- 观察到的效应有多大？
+12% absolute DFS at 3 years.
- 研究结果对日常生活意味着什么？
Benefit clearly exceeds the cardiac risk for most patients; heart monitoring is needed.
- 该研究有哪些局限？
Interim analysis.
- 它对 Elawady 的具体说法说明了什么？
Documents harm and much larger benefit.
- 研究结果是否适用于德国和欧洲？
High.
- 从该研究中明确不能得出什么结论？
That treatment should be avoided.
-
Chemotherapy for early breast cancer: benefits and risks in 100,000 women
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4Meta分析独立交叉核查已核查全文★ 关键研究Anthracycline-taxane chemotherapy lowered recurrence and breast-cancer death; it caused about one extra leukaemia per 700 women and no measurable excess heart deaths within about 5 years.
Confirms anthracycline harms are dose-related but found no excess cardiovascular death within about 5 years in trial populations.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Weigh benefits and risks of anthracycline-containing chemotherapy
- 研究是如何开展的？
Pooled individual data from randomised trials
- 研究了多少人、动物或样本？
18,103 women in the main comparison; about 100,000 overall
- 实际发现了什么？
Fewer recurrences (RR 0.86) and fewer breast-cancer deaths; AML 0.18% vs 0.03%
- 观察到的效应有多大？
10-year recurrence 16.4% vs 18.9%; up to 8.7 points fewer recurrences with concurrent anthracycline
- 研究结果对日常生活意味着什么？
For every leukaemia caused, roughly 18 recurrences are prevented in this data set
- 该研究有哪些局限？
Short follow-up for heart effects; high-risk heart patients often excluded
- 它对 Elawady 的具体说法说明了什么？
Harms of chemotherapy are real (AML) but small compared with the benefit; this contradicts the idea that harms outweigh benefits
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot quantify heart failure 15-20 years after treatment
-
Can heart damage from anthracyclines be prevented?
de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2Meta分析独立交叉核查已核查摘要Dexrazoxane cut heart failure in adults by about four-fifths without lowering cancer control.
Confirms that anthracycline cardiotoxicity is real and shows it can be reduced; supports monitoring/prevention rather than avoidance.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test a heart-protecting drug
- 研究是如何开展的？
Cochrane review of RCTs
- 研究了多少人、动物或样本？
13 trials, about 2500 patients
- 实际发现了什么？
Less heart failure in adults
- 观察到的效应有多大？
RR 0.22
- 研究结果对日常生活意味着什么？
Heart damage from chemotherapy can be reduced
- 该研究有哪些局限？
Weaker evidence in children; possible second-cancer signal
- 它对 Elawady 的具体说法说明了什么？
Harm is real but manageable
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Not a reason to avoid treatment
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Cardio-oncology surveillance and prevention are part of European practice: the 2022 ESC cardio-oncology guideline (first ESC guideline on the topic) covers definition, diagnosis, treatment and prevention of cancer-therapy-related cardiovascular toxicity before, during and after treatment (ESC guideline page fetched 2026-10-26; detailed recommendations not audited). Dexrazoxane reduced clinical heart failure in adults by about four-fifths without reducing cancer control (RR 0.22, 0.11-0.43; I-CHM-109).
埃及
Anthracyclines and chest radiotherapy are used in Egypt. The Egyptian Society of Cardiology is listed among the national societies endorsing the 2022 ESC cardio-oncology guideline. No Egyptian data on the frequency of cardiotoxicity in patients were found (searches found mainly animal studies).
在我的国家适用什么？
一般科学评估
正确 蒽环类药物和胸部放疗的心脏毒性确实存在，且呈剂量依赖性；它可以被监测，也可以治疗。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.. Cardinale D et al.. Circulation 2015 · PMID 25948538 · DOI 10.1161/CIRCULATIONAHA.114.013777
- Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.. Lipshultz SE et al.. N Engl J Med 1991 · PMID 1997853 · DOI 10.1056/NEJM199103213241205
- Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort.. Mulrooney DA et al.. BMJ 2009 · PMID 19996459 · DOI 10.1136/bmj.b4606
- Risk of ischemic heart disease in women after radiotherapy for breast cancer.. Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.. Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
- Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.. Swain SM et al.. Cancer 2003 · PMID 12767102 · DOI 10.1002/cncr.11407
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.. Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2023 · PMID 37061269 · DOI 10.1016/S0140-6736(23)00285-4
- Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.. de Baat EC et al.. Cochrane Database Syst Rev 2022 · PMID 36162822 · DOI 10.1002/14651858.CD014638.pub2